Adrian Johnson

TLDR: – Venture funding in AI has been skyrocketing, with large rounds for companies like Figure and Lambda. – M&A remains the most common exit path for VC-backed AI startups, although the

TLDR: Fin+Tech has selected 14 startups for its third acceleration program. Selected startups completed a 4-month acceleration program with potential investments of up to €300,000. CDP Venture Capital’s accelerator, Fin+Tech, has announced

TLDR: African venture capital rebounds with Partech Africa’s second fund Global LPs reinvest in the fund, with some doubling their commitments Africa experienced a slowdown in venture capital funding last year, but

TLDR: Bristol emerging as a prominent innovation center in the UK Significant increase in funding for Bristol-based startups across various industries In 2024, Bristol is seen as a significant innovation center in

TLDR: Women-led AI startups are being left behind in terms of investment, with only 0.7% of capital invested in the AI software subsector going to startups led by women. The lack of

TLDR: The Pentagon abruptly stopped funding Shift, a fellowship program connecting startups and VCs with military personnel for defense technology innovation. The decision was made due to “funding constraints” and expected cuts

TLDR: CalPERS plans to increase its private equity allocation from 13% to 17%, with a focus on venture capital and growth funds. This move is expected to benefit VCs. Article Summary: California

TLDR: Victoria’s state-run $2 billion venture capital fund, Breakthrough Victoria, is under scrutiny for lack of transparency and high risks involved. There are calls to scrap the fund as Victoria faces record

Article Summary TLDR: Victoria’s state-run $2 billion venture capital fund, Breakthrough Victoria, is under scrutiny for lack of transparency. The fund, created in 2020, aims to invest in startups and expanding businesses

TLDR: BrickBio, a biotechnology company in Boston, received an investment from Samsung Ventures. The investment amount was not disclosed, but it will support the development of protein engineering technology and preclinical assets.